Terbinafine, Betamethasone Acetate

Verify with FDA CVM →

19 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Terbinafine, Betamethasone Acetate

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 19

Most Affected Breeds

Retriever - Golden 5
Dog (unknown) 3
Deutsche Dogge, Great Dane 1
Vallhund - Swedish 1
Beagle 1
Spaniel - King Charles Cavalier 1
Crossbred Canine/dog 1
Spaniel - Springer English 1
Retriever - Labrador 1
Boxer (German Boxer) 1

Most Reported Reactions

Lack of efficacy - NOS 10
Ear infection NOS 3
Head shake - ear disorder 3
Application site reddening 2
Application site scratching 2
Application site pain 2
Application site lesion 1
Drowsiness - systemic disorder 1
Impaired hearing 1
Vomiting 1
Diarrhoea 1
Lethargy (see also Central nervous system depression in Neurological) 1

Outcome Breakdown

Outcome Unknown
11 (57.9%)
Recovered/Normal
5 (26.3%)
Ongoing
3 (15.8%)

Data Summary

Metric Value
Total adverse event reports 19
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 1
Distinct breeds in reports 13
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Terbinafine, Betamethasone Acetate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 19 adverse event reports referencing Terbinafine, Betamethasone Acetate, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Terbinafine, Betamethasone Acetate. Reported administration routes include Auricular (Otic), Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Terbinafine, Betamethasone Acetate reports are Dog (19 reports), with Dog accounting for the largest share. Within those species, Retriever - Golden (5), Dog (unknown) (3), Deutsche Dogge, Great Dane (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Terbinafine, Betamethasone Acetate are Lack of efficacy - NOS (10), Ear infection NOS (3), Head shake - ear disorder (3), Application site reddening (2). Of the 19 reports with a coded outcome, Outcome Unknown is the leading category at 57.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Terbinafine, Betamethasone Acetate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial